Osteoprotegerin polyclonal, anti-human, mouse, rat, bovine, horse, pig

Protein Family: Cellular Antigens, Receptors and Channels

Pathway and Disease: Development and Behavior, Signaling Molecules and Interaction

Description:
Osteoprotegerin (OPG) acts as a decoy receptor for RANKL by neutralizing its function in osteoclastogenesis. OPG inhibits osteoclast activation and promotes osteoclast apoptosis in vitro. OPG is up-regulated by increasing calcium concentration and estrogens. Defects in OPG are the cause of juvenile Paget disease, which is characterized by rapid bone remodeling leading to deformities, fractures ans osteopenia.

Alternate Names: Tumor necrosis factor receptor superfamily member 11B, Osteoprotegerin, Osteoclastogenesis inhibitory factor, TNFRSF11B, OCIF, OPG

Application Notes: E: 1:500-1:1,000; WB: 1:200-1:500; IHC: 1:200-1:500

Accession No.: O00300

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human osteoprotegerin.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 25% glycerol, 1 mg/ml BSA with 0.09% sodium azide. Antibody was purified by Protein-A affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.

Product Citations:
[1] Ray S et al. 2017. Biomaterials. 157: 1-16. PMID 29216500.
[2] Ray S et al. 2016. Injury. Suppl 1:S52-61. PMID 26768293.
[3] Thormann U et al. 2013. Biomaterials. PMID 23906515.
[4] Fradet A et al. 2011. Cancer Research. 71(17): 5728-5738. PMID 21734015.
[5] Fradet A et al. 2013. PLoS ONE. 8(9):e75092. PMID 24069383.